Allergic rhinitis

Small, Peter; Keith, Paul K.; Kim, Harold

doi:10.1186/s13223-018-0280-7

Cited by 238 publications

(277 citation statements)

References 42 publications

Supporting

Mentioning

243

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of allergic diseases is a serious problem in the field of modern medicine and public health. Estimates suggest that 10% to 30% of adults and up to 40% of children suffer from allergic rhinitis (AR), and the prevalence of the disorder is increasing . Symptoms can have significant negative impact on the patients’ quality of life (QoL), sleep quality, mood, learning achievement, and sexual dysfunction…”

Section: Introductionmentioning

confidence: 99%

“…Estimates suggest that 10% to 30% of adults and up to 40% of children suffer from allergic rhinitis (AR), 1 and the prevalence of the disorder is increasing. 2 Symptoms can have significant negative impact on the patients' quality of life (QoL), sleep quality, mood, learning achievement, and sexual dysfunction. 3 Treatment for AR continues to be based on allergen avoidance, medications that provide symptomatic relief, anti-inflammatory therapies, and allergy immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Add‐on probiotics in patients with persistent allergic rhinitis: A randomized crossover clinical trial

et al. 2019

View full text Add to dashboard Cite

Objectives Current medications for allergic rhinitis (AR) may have undesirable side effects that could affect quality of life (QoL). Probiotics could be an alternative in these patients. The aim of this study was to assess the impact of add‐on probiotics on symptoms and QoL of patients. Methods In this randomized crossover clinical trial, patients with persistent AR were included. Each subject received budesonide with probiotic supplements (BP) or budesonide with placebo for 8 weeks (B), then vice versa for a further 8 weeks. There was an 8‐week washout. The primary outcome was the change of the Short Form 36‐Item Health Survey (SF‐36) score. The secondary outcomes were assessed by the Sinonasal Outcome Test‐22 (SNOT‐22) and the Control of Allergic Rhinitis and Asthma Test (CARAT) questionnaires. Results A total of 152 subjects (30.1 ± 7.6 years) completed the study. The SF‐36 score in both groups showed improvement compared with baseline values. Treatment BP was more effective than that of B. The Cohen's d and the number needed to treat for Physical Component Scales of SF‐36 were 0.40 and 10.77, respectively. These values for Mental Component Scales were 0.33 and 12.61, respectively. Also, treatment BP showed more reduction in the score of SNOT‐22 and CARAT. Conclusion This study showed that the addition of probiotics to budesonide significantly improved QoL in persistent AR patients. However, the clinical situation of these patients may be not very representative of AR patients in general population. Further studies are recommended. Level of Evidence 1bLaryngoscope, 129:1744–1750, 2019

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Add‐on probiotics in patients with persistent allergic rhinitis: A randomized crossover clinical trial

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Those who also have allergic conjunctivitis experience redness, tears and itching of the eyes 27 . The goal of treatment in allergic rhinoconjunctivitis is symptom relief.…”

Section: Adults With Allergic Rhinitismentioning

confidence: 99%

Bilastine: a lifetime companion for the treatment of allergies

Church

Tiongco-Recto

Ridolo

et al. 2019

Current Medical Research and Opinion

View full text Add to dashboard Cite

Objective: Bilastine is a potent and highly selective H 1 -antihistamine approved for the treatment of allergic rhinoconjunctivitis and urticaria. This article summarizes available data on the use of bilastine in the treatment of allergic disorders in different age groups, including younger and older adults, and school-age children and adolescents. Methods: A PubMed literature search ("bilastine") was conducted on 25 February 2019. Additional literature known to the authors and identified from the reference lists of cited publications was included. Results: Bilastine is administered orally at a dose of 20 mg once daily in adults and adolescents aged 12 years and 10 mg once daily in children aged 6 to <12 years. Clinical trials have demonstrated its efficacy at improving nasal and ocular symptoms in patients with allergic rhinitis, and wheals and itching in patients with urticaria. It has a rapid onset of action and long duration of action. Bilastine does not undergo significant metabolism and does not interact with the CYP450 system, which limits its potential for drug-drug interactions. No dosage adjustments are required in patients with renal or hepatic impairment, or in the elderly. Bilastine is generally well tolerated, even when administered at above-standard doses. It does not exhibit anticholinergic effects or cardiotoxic effects, shows no central nervous system penetration and has minimal sedative properties. It has been shown to improve health-related quality of life. Conclusions: Bilastine is a suitable option for the treatment of patients with allergic rhinoconjunctivitis or urticaria across age groups from school-age children to elderly patients.

show abstract

“…These diseases are driven by a familial or personal tendency to induce immunoglobulin (Ig)E antibodies and sensitization in response to different stimuli [5]. Genetic and environmental factors play a role in atopic diseases [6][7][8][9]. Currently, 20% of the population in the western world suffers from AD and 5-8% of patients with AD have co-occurrence of food allergies [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Microbial interactions in the atopic march

Nibbering

Ubags

2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Summary The human body is populated by a large number of microorganisms and exist in symbiosis with these immensely diverse communities, which are suggested to influence health and disease. The microbiota plays an essential role in the maturation and function of the immune system. The prevalence of atopic diseases has increased drastically over the past decades, and the co‐occurrence of multiple allergic diseases and allergic sensitization starting in early life has gained a great deal of attention. Immune responses in different organs affected by allergic diseases (e.g. skin, intestine and lung) may be linked to microbial changes in peripheral tissues. In the current review, we provide an overview of the current understanding of microbial interactions in allergic diseases and their potential role in the atopic march.

show abstract

Allergic rhinitis

Cited by 238 publications

References 42 publications

Add‐on probiotics in patients with persistent allergic rhinitis: A randomized crossover clinical trial

Add‐on probiotics in patients with persistent allergic rhinitis: A randomized crossover clinical trial

Bilastine: a lifetime companion for the treatment of allergies

Microbial interactions in the atopic march

Contact Info

Product

Resources

About